Comprehensive Adrenergic Agonists and Sympathomimetic Pharmacology
Foundations and Autonomic Recap
Muscarinic Receptor Subtypes and Physiology:
Muscarinic receptors ( through ) mediate the "rest and digest" functions of the parasympathetic nervous system.
Receptors: Primarily localized to the cardiovascular system (cardiac myocytes and nodal tissue). Activation produces negative chronotropic and negative inotropic effects, leading to bradycardia and reduced cardiac output.
Receptors: Mediate smooth muscle contraction and glandular secretion throughout the viscera. Activation produces bronchoconstriction, increased gastrointestinal motility (nausea, cramping, diarrhea), pupillary constriction (miosis), detrusor muscle contraction leading to urination, and general housekeeping/secretory functions.
Anticholinergic Toxicity and Clinical Applications:
Blockade of muscarinic receptors produces classic anticholinergic side effects: xerostomia (dry mouth), constipation, urinary retention, blurred vision, and anhidrosis.
Therapeutic indications derived from these actions include:
Scopolamine: Used for motion sickness.
Antimuscarinic bronchodilators: Produce bronchodilation by relaxing airway smooth muscle; utilized extensively in chronic obstructive pulmonary disease (COPD) and asthma.
Sympathetic Nervous System Organization and Neurochemistry:
Anatomical Origin: Thoracolumbar outflow (originates in the thoracic and lumbar segments of the spinal cord) and projects through the sympathetic chain ganglia, creating a diffuse, systemic physiological response.
Preganglionic Neurotransmitter: Acetylcholine ().
Postganglionic Sympathetic Neurotransmitter: Norepinephrine () in most peripheral tissues.
Renal Vasculature Neurotransmitter: Dopamine.
Adrenal Medullary Secretion: Epinephrine () and Norepinephrine ().
Enzymatic basis: The conversion of norepinephrine to epinephrine requires phenylethanolamine N-methyltransferase (), an enzyme expressed in adrenal medullary chromaffin tissue but absent in postganglionic sympathetic axons.
Historical Classification and Receptor Signaling
The 1948 Ahlquist Receptor Delineation:
In 1948, the foundational framework of adrenergic pharmacology was established by comparing the potency orders of three catecholamines: Epinephrine (), Norepinephrine (), and Isoproterenol (isopropanol):
Vasoconstriction / Contraction: Epinephrine > Norepinephrine > Isoproterenol. These contractile sites were designated (alpha) adrenergic receptors.
Vasodilation / Relaxation: Isoproterenol > Epinephrine > Norepinephrine. These inhibitory/relaxing sites were designated (beta) adrenergic receptors.
Receptor Subtypes and Intracellular Signal Coupling:
Adrenergic receptors belong to the G-protein-coupled receptor (GPCR) superfamily.
Subtypes (): Coupled to proteins; activates phospholipase C (), generating inositol trisphosphate () and diacylglycerol (), which elevates intracellular calcium () to produce smooth muscle contraction.
Subtypes (): Coupled to proteins; inhibits adenylyl cyclase, causing a decrease in intracellular cyclic adenosine monophosphate (). Primarily localized presynaptically as inhibitory autoreceptors to suppress neurotransmitter release.
Subtypes (): All coupled to proteins; activates adenylyl cyclase, causing an increase in intracellular and protein kinase A () activation.
Broad Classification of Adrenergic Agonists
Direct-Acting Sympathomimetics:
Bind directly to adrenergic receptors, exhibiting high intrinsic affinity and efficacy that mimics endogenous catecholamines.
Selective Agents: Phenylephrine (), Clonidine (), Dobutamine (), Metaproterenol/Albuterol (), Mirabegron ().
Nonselective Agents: Epinephrine (), Norepinephrine (), Isoproterenol ().
Indirect-Acting Sympathomimetics:
Do not activate adrenergic receptors directly; increase synaptic concentrations of endogenous norepinephrine via three distinct mechanisms:
Facilitating presynaptic vesicular release: Amphetamine, Tyramine.
Inhibiting the Norepinephrine Transporter (NET / Reuptake-1): Cocaine, Tricyclic Antidepressants (TCAs).
Inhibiting enzymatic degradation: Monoamine Oxidase () inhibitors, Catechol-O-methyltransferase () inhibitors.
Mixed-Acting Sympathomimetics:
Possess dual mechanisms: directly stimulate postsynaptic and receptors while concurrently promoting the displacement and release of stored presynaptic norepinephrine.
Prototypes: Ephedrine, Pseudoephedrine.
Adrenergic Receptor Cheat Sheet and Target Organ Effects
Adrenergic Receptors:
Vascular Smooth Muscle: Vasoconstriction, leading to increased total peripheral resistance () and elevated systemic blood pressure.
Ocular: Contraction of the pupillary radial dilator muscle, producing pupillary dilation (mydriasis).
Genitourinary: Contraction of the internal urinary sphincter and trigone muscle of the bladder, promoting urinary retention.
Central Nervous System: General CNS stimulation.
Adrenergic Receptors:
Presynaptic Neuronal Terminals: Negative feedback autoreceptors; their stimulation decreases further exocytotic release of norepinephrine.
Central Nervous System: Brainstem activation suppresses central sympathetic outflow, reducing baseline arterial pressure.
Pancreas: Decreases insulin release from pancreatic beta cells, maintaining circulating glucose levels.
Adrenergic Receptors:
Myocardium and Cardiac Conduction: Positive inotropy (increased force of myocardial contraction) and positive chronotropy (increased heart rate), increasing overall cardiac output () and myocardial oxygen demand.
Renal Juxtaglomerular Apparatus: Stimulates the release of renin, converting angiotensinogen to angiotensin I, which downstream increases angiotensin II to promote secondary vasoconstriction.
Adrenergic Receptors:
Bronchial Smooth Muscle: Potent bronchodilation; primary target for asthma and COPD.
Vascular Beds: Vasodilation in large vessels supplying skeletal muscle and splanchnic viscera, causing a localized reduction in vascular resistance.
Uterine Smooth Muscle: Relaxes the myometrium, inhibiting uterine tone and labor contractions.
Metabolic: Stimulates glycogenolysis in skeletal muscle and liver tissue to mobilize glucose.
Adrenergic Receptors:
Urinary Bladder: Exclusively expressed on the detrusor smooth muscle; induces detrusor relaxation during the filling phase to enhance bladder storage capacity.
Does not exert direct contractile activity on the internal sphincter (which is under control).
Endogenous Adrenergic Agonists
Epinephrine ():
Receptor Profile: Potent universal agonist across and receptors.
Hemodynamic Actions:
Low-Dose Administration: High sensitivity of receptors causes vasodilation in skeletal muscle vascular beds, decreasing systemic peripheral resistance and lowering diastolic blood pressure. Concurrent stimulation increases cardiac contractility, pulse rate, and systolic blood pressure.
High-Dose Administration: -mediated vasoconstriction overrides -mediated vasodilation, increasing both peripheral resistance and systemic diastolic blood pressure.
Net Biological Outcome: Redistribution of blood flow during "fight-or-flight" states—vasoconstriction in cutaneous and mucosal beds () with concurrent shunting of blood toward working skeletal muscle ().
Visceral and Smooth Muscle Effects:
Gastrointestinal: Inhibition of motility and tone due to smooth muscle relaxation.
Respiratory: Relaxes bronchial smooth muscle () and reduces mucosal edema/secretions ().
Genitourinary: Relaxes the detrusor muscle () and constricts the bladder sphincter (), preventing micturition.
Uterine: Inhibits contractions during the final trimester of pregnancy; historically used to postpone premature labor in threatened abortion.
Metabolic Regulation:
Stimulates glycogenolysis () to release glucose into the circulation.
Inhibits pancreatic insulin release (), attenuating tissue uptake and storage of glucose.
Increases circulating free fatty acids via lipolysis ().
Pharmacokinetics and Formulations:
Ineffective orally due to rapid gastrointestinal and hepatic degradation by and .
Routes of Administration: Subcutaneous (SC), intramuscular (IM, e.g., EpiPen), intravenous (IV), intraspinal, inhalation, and topical.
Adverse Effects and Interactions:
Anxiety, apprehension, restlessness, peripheral tremors, headache, palpitations, and cardiac arrhythmias.
Toxicity is potentiated by inhibitors, TCAs, and antihistamines.
Pharmacologically antagonized by -blockers.
Therapeutic Applications:
Drug of choice (first-line) for anaphylactic shock (IM auto-injector):
stimulation revives depressed cardiac output and heart rate.
stimulation reverses severe bronchoconstriction.
stimulation reverses peripheral vasodilation and angioedema.
Advanced cardiac life support (ACLS) for cardiac arrest.
Severe acute bronchospasm refractory to selective agents.
Formulated with local anesthetics (e.g., lidocaine with epinephrine):
Produces localized -mediated vasoconstriction.
Prevents vascular washout and systemic absorption of the local anesthetic, thereby prolonging its duration of action and minimizing systemic toxicity (never administered intravenously in this co-formulation).
Norepinephrine ():
Receptor Profile: Potent agonist at and receptors; lacks significant activity at receptors.
Hemodynamic Profile and Reflex Bradycardia:
Lack of -mediated vasodilation results in unopposed, intense -mediated vasoconstriction.
Total peripheral resistance rises steeply, causing a dramatic elevation in both systolic and diastolic arterial pressures.
Reflex Mechanism: The steep increase in mean arterial pressure triggers high-pressure carotid and aortic baroreceptors, producing compensatory vagal (parasympathetic) stimulation to the sinoatrial () node.
Clinical Consequence: Manifests as reflex bradycardia in intact physiological systems, causing the observed pulse rate to drop despite direct myocardial stimulation (in denervated or isolated myocardial tissue lacking baroreceptor reflexes, tachycardia would prevail).
Pharmacokinetics and Toxicity:
Inactive orally; administered strictly via continuous IV infusion.
Extravasation Hazard: Local leakage into peripheral soft tissues causes intense, sustained ischemic vasoconstriction, which can lead to ischemic necrosis and tissue sloughing.
Interactions: Concomitant cyclopropane or halothane anesthesia dramatically increases the risk of severe ventricular arrhythmias and fibrillation.
Therapeutic Indications: First-line vasopressor for profound hypotension in shock states, particularly septic shock, where vascular tone is pathologically depleted.
Dopamine:
Biosynthetic Role: Synthesized in the cytoplasm from L-DOPA, transported into storage vesicles by the vesicular monoamine transporter (VMAT), and subsequently converted to norepinephrine by dopamine -hydroxylase ().
Receptor Selectivity and Dose-Dependent Hemodynamics:
Low-Dose Infusion: Stimulates vascular receptors, causing selective vasodilation of renal, mesenteric, and coronary vascular beds, which elevates renal blood flow and visceral perfusion.
Intermediate-Dose Infusion: Stimulates myocardial receptors, enhancing cardiac contractility and cardiac output (positive inotropy and chronotropy).
High-Dose Infusion: Overcomes dopaminergic vasodilation by stimulating vascular receptors, producing widespread systemic vasoconstriction and raising blood pressure.
Pharmacokinetics and Clinical Utility:
Orally inactive; administered via continuous IV infusion; rapidly inactivated by and .
Adverse Effects: Nausea, vomiting, tachycardia, and exacerbation of myocardial angina.
Indications: Cardiogenic shock, septic shock, acute heart failure, and refractory states characterized by low cardiac output and renal hypoperfusion.
Neurological Connection: Central dopamine receptor agonists manage Parkinson's disease; central receptor antagonists act as antipsychotics.
Direct-Acting Selective Adrenergic Agonists
-Selective Agonists (Phenylephrine):
Prototype: Phenylephrine.
Related Agents: Oxymetazoline and Tetrahydrozoline (possess and partial activity).
Hemodynamic Effects: Stimulates receptors on vascular smooth muscle, producing peripheral vasoconstriction, elevated vascular resistance, and an acute rise in systemic blood pressure accompanied by compensatory reflex bradycardia.
Therapeutic Uses:
Ophthalmic: Formulated as over-the-counter (OTC) eye drops to induce vasoconstriction for ocular hyperemia (red eye).
Anesthetic Management: Maintenance of vascular tone and perfusion pressure during inhalation or spinal anesthesia.
Cardiac: Historically utilized to terminate paroxysmal supraventricular tachycardia () via vagal reflex induction.
Decongestant Status: Historically used in OTC oral cold formulations. The FDA advisory committee determined that oral phenylephrine is ineffective as a nasal decongestant at standard recommended doses; however, topical nasal sprays remain clinically effective.
Clinical Warning: Hypertensive patients taking OTC agonists risk precipitating acute hypertensive crises.
-Selective Agonists (Clonidine):
Prototypes and Related Agents: Clonidine, Tizanidine (indicated as a central muscle relaxant), Guanfacine (utilized in ADHD).
Decreases sympathetic flow, slow the body.
Mechanism of Action: Crosses the blood-brain barrier to stimulate presynaptic receptors in the brainstem, attenuating sympathetic outflow to the peripheral vasculature, reducing vascular tone, and lowering blood pressure.
Pharmacokinetics: Active orally with complete () bioavailability; approximately of the parent drug is eliminated unchanged in the urine.
Side Effects and Toxicity:
Sedation and CNS depression (prominent drowsiness due to reduced sympathetic tone).
Dry mouth (xerostomia), constipation, dry eyes, and orthostatic hypotension.
Contraindicated or antagonized by tricyclic antidepressants (TCAs), which inhibit norepinephrine reuptake and counteract central presynaptic inhibition.
Clinical Applications: Second-line management of hypertension (especially in complex co-morbidities like diabetes), attention-deficit/hyperactivity disorder (ADHD), and off-label mitigation of autonomic withdrawal symptoms during opioid detoxification.
Nonselective -Agonists (Isoproterenol):
Prototype: Isoproterenol (isopropanol).
Receptor Profile: Potent agonist at both and receptors with negligible affinity for receptors.
Hemodynamics:
stimulation causes intense positive inotropic and chronotropic responses, increasing pulse rate and systolic blood pressure.
stimulation causes profound, unopposed peripheral vasodilation, leading to a steep decline in total peripheral resistance and diastolic blood pressure.
Adverse Effects: Severe tachycardia, palpitations, facial flushing, headache, and cardiac arrhythmias.
Therapeutic Uses: Emergency management of severe bradycardia, heart block, or as temporary support prior to electronic pacemaker insertion.
-Selective Agonists (Dobutamine):
Prototype: Dobutamine.
Receptor Profile: Selective adrenergic agonist with minimal or activity.
Hemodynamic Action: Operates as an inotrope to enhance myocardial contractility and stroke volume, with comparatively less chronotropic acceleration or peripheral vascular disruption.
Pharmacokinetics: Administered via intravenous infusion; rapid onset within , with peak pharmacological response occurring up to .
Therapeutic Indications: Short-term inotropic support for acute decompensated heart failure, cardiogenic shock, and low cardiac output states.
Adverse Effects: Tachycardia, ventricular arrhythmias, headache, and nausea.
-Selective Agonists (SABAs, LABAs, and Ultra-LABAs):
Sub-classification Schema:
Short-Acting Agonists (SABA): Metaproterenol, Albuterol. Rapid onset; indicated for the immediate relief ("rescue") of acute bronchospasm.
Long-Acting Agonists (LABA): Salmeterol, Formoterol. Extended duration (); indicated for maintenance and prophylaxis in asthma and COPD (never as rescue monotherapy).
Ultra-Long-Acting Agonists (Ultra-LABA): Once-daily maintenance options approved for COPD.
Metaproterenol (SABA):
Relaxes bronchial smooth muscle; resistant to degradation; orally or inhalational active.
GI upset, tremor.
Vasodilator.
Treat acute asthma and bronchospasm.
Excessive dosing causes crossover to receptors, precipitating fine skeletal muscle tremors, nervousness, tachycardia, and hypertension.
Salmeterol (LABA):
Possesses greater selectivity for receptors compared to albuterol.
Maintenance or prophalaxis. In an attack, need albuterol.
Mechanism: Stimulates intracellular production and inhibits the release of inflammatory hypersensitivity mediators from mast cells.
Slow onset precludes its use for acute bronchospasm; indicated strictly as maintenance therapy in conjunction with inhaled corticosteroids (ICS) for asthma and COPD.
Interactions: Concomitant administration with strong cytochrome P450 3A4 (CYP3A4) inhibitors is contraindicated due to impaired clearance.
Respiratory Combination Principles:
Acute Exacerbations: SABA combined with Short-Acting Muscarinic Antagonist (SAMA, e.g., albuterol plus ipratropium).
Maintenance Therapy: LABA combined with Long-Acting Muscarinic Antagonist (LAMA, e.g., salmeterol or formoterol plus tiotropium).
-Selective Agonists (Mirabegron):
Prototype: Mirabegron.
Mechanism of Action: Selectively binds receptors on the bladder detrusor muscle, stimulating smooth muscle relaxation during the storage/filling phase to increase functional bladder capacity without altering internal sphincter tone.
Pharmacokinetics: High oral bioavailability and prolonged elimination half-life, allowing once-daily dosing.
Therapeutic Applications: First-line management of overactive bladder (OAB) presenting with urge incontinence, urgency, and frequency; approved in pediatric patients aged .
Key Clinical Advantage: Lacks the antimuscarinic side-effect profile of agents like darifenacin or oxybutynin, avoiding central anticholinergic confusion, delirium, and elevated fall risks in elderly populations.
Adverse Effects: Dose-dependent spillover onto receptors can cause hypertension and tachycardia; also associated with nasopharyngitis, headaches, and urinary tract infections ().
Drug Interactions: Moderate inhibitor of CYP2D6.
Indirect-Acting Adrenergic Agonists
Neurotransmitter Releasing Agents (Amphetamines):
Prototypes and Formulations: Amphetamine, Dextroamphetamine, Methamphetamine. Formulated as mixed amphetamine salts (Adderall: dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, and amphetamine sulfate).
Mechanisms of Action:
Enters presynaptic terminals and displaces endogenous norepinephrine and dopamine from vesicular storage pools.
Inhibits the catecholamine reuptake transporters NET and DAT.
Acts as a weak inhibitor of monoamine oxidase ().
Exerts no significant direct agonist activity on postsynaptic adrenergic receptors.
Central and Somatic Pharmacology:
CNS: Induces wakefulness, heightened alertness, mood elevation, reduced physical and mental fatigue, and enhanced motor performance.
Neurobiology of ADHD: Individuals with ADHD often exhibit deficient baseline dopamine signaling in executive and reward circuits, leading to compensatory stimulation-seeking behavior; amphetamines elevate synaptic dopamine and norepinephrine to stabilize attention and reduce distractibility.
Cardiovascular: Elevations in systolic and diastolic blood pressure, potential reflex bradycardia at therapeutic doses, and cardiac arrhythmias at toxic levels.
Metabolic: Suppresses hypothalamic appetite centers, producing anorexia and progressive weight loss.
Clinical Considerations and Counseling:
Side Effects: Severe insomnia, euphoria, restlessness, dizziness, anorexia, hypertension, and tachycardia.
Dosing Timing: School-aged children should take medication in the morning and early afternoon; late-day dosing must be avoided to prevent insomnia.
Urine pH Interactions: Reabsorption and clearance depend on urinary pH; alkalinizers potentiate toxicity by increasing tubular reabsorption, whereas acidifiers accelerate elimination.
Historical and Structural Context:
Synthesized in 1887 by Romanian chemist Lazar Edeleanu.
Commercialized in 1933 as the Benzedrine inhaler ("Bennies").
Distributed extensively as "pep pills" during World War II; American and British forces consumed an estimated doses, with concurrent use by German, Japanese, and Axis forces (including daily injections to Adolf Hitler).
Removed from OTC distribution in the United States in 1956.
Structure-Activity Relationship: The addition of a single methyl group () to the terminal amine of amphetamine yields methamphetamine, which markedly enhances central nervous system penetration, euphoria, addictive liability, and neurotoxicity.
Catecholamine Reuptake Inhibitors:
Tricyclic Antidepressants (TCAs): Agents such as Imipramine and Amitriptyline nonselectively inhibit the reuptake of norepinephrine, serotonin, and dopamine via the NET and SERT transporters, leading to accumulation of catecholamines in the synaptic cleft.
Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs): Agents such as Duloxetine and Venlafaxine inhibit NET and SERT with improved adverse effect profiles relative to TCAs.
Selective Norepinephrine Reuptake Inhibitors (NRIs): Agents such as Atomoxetine selectively block NET; indicated for ADHD.
Cocaine: Blocks NET (Uptake-1) and DAT, amplifying peripheral sympathomimetic and central dopaminergic responses.
Enzymatic Degradation Inhibitors ( and Inhibitors):
Monoamine Oxidase Inhibitors ():
Inhibitors: Nonselectively inhibit the oxidative deamination of norepinephrine, serotonin, and dopamine; historically used for refractory major depression.
Tyramine Crisis: Ingestion of tyramine-rich foods (aged cheeses, draft beer, red wine, cured meats) alongside inhibitors prevents gastrointestinal tyramine degradation. Systemically absorbed tyramine triggers massive vesicular norepinephrine release, inducing life-threatening hypertensive crisis.
Inhibitors: Selectively degrade dopamine at therapeutic levels; used in Parkinson's disease; exempt from dietary tyramine restrictions.
Inhibitors: Agents such as Entacapone inhibit Catechol-O-methyltransferase, preventing peripheral degradation of catecholamines; used as adjuncts in Parkinson's disease therapy.
Mixed-Acting Adrenergic Agonists
Pharmacology of Ephedrine and Pseudoephedrine:
Mechanism of Action: Bimodal sympathomimetic activity:
Directly stimulates postsynaptic and receptors.
Induces non-vesicular release of stored norepinephrine from presynaptic neuronal terminals.
Pharmacokinetics: Orally active with high bioavailability; resistant to degradation by both and , resulting in an extended elimination half-life and prolonged duration of clinical effect.
Cardiovascular and Systemic Effects: Increases systolic and diastolic blood pressure, stimulates cardiac contractility (), and causes bronchodilation ().
Adverse Effects: Insomnia, central nervousness, anxiety, urinary retention, cardiac palpitations, diaphoresis, and anorexia.
Drug Interactions and Washout: Concomitant use with inhibitors is contraindicated. Initiating or switching between monoaminergic antidepressants requires a strict washout period to avoid fatal hypertensive or serotonergic crises.
Therapeutic Uses:
Vasopressor agent for correcting hypotension during spinal anesthesia.
Decongestant formulations (contraindicated in hypertensive patients).
Adjuvant therapy for narcolepsy, depressive states, myasthenia gravis, and historical management of asthma/COPD.
Regulatory Note: Ephedrine and pseudoephedrine sales are legally restricted because they serve as essential chemical precursors in the clandestine synthesis of methamphetamine.
Interactive Review and Discussion
Sympathetic Structural Organization:
Question: Where are the cell bodies of preganglionic sympathetic neurons located, and how is the outflow described?
Answer: Located in the thoracolumbar region of the spinal cord (thoracic and lumbar segments); the physiological output is anatomical and functional diffuse, preparing the entire organism for flight or fright.
Adrenergic Influence on Gastrointestinal Motility:
Question: True or False: Epinephrine increases gastrointestinal motility.
Answer: False. Sympathetic stimulation relaxes gastrointestinal smooth muscle and halts peristalsis to divert metabolic energy toward survival.
Co-formulation with Local Anesthetics:
Question: What is the pharmacological rationale for combining epinephrine with lidocaine?
Answer: Epinephrine stimulates local receptors, causing vasoconstriction. This reduces local blood flow, slows vascular clearance/washout of lidocaine, and extends the duration of local anesthesia while limiting systemic toxicity.
Metabolic Effects of Sympathomimetic Stimulation:
Question: What are the cumulative metabolic effects of norepinephrine and epinephrine?
Answer: Promotion of glycogenolysis, elevation of circulating free fatty acids via lipolysis, and inhibition of insulin release mediated by receptors, all working to maximize circulating energy substrates.
Receptor Mediation of Pancreatic Secretion:
Question: Which receptor mediates epinephrine-induced inhibition of insulin release?
Answer: Presynaptic/pancreatic inhibitory receptors.
Genitourinary Control:
Question: How do adrenergic agonists modulate micturition?
Answer: Stimulation of receptors relaxes the detrusor muscle, while stimulation of receptors constricts the internal sphincter and trigone, producing urinary retention.
Cardiac Contractility and Rate:
Question: Which receptor mediates positive inotropic and positive chronotropic cardiovascular responses?
Answer: adrenergic receptors.
Vascular Dynamics:
Question: Which receptor subtype mediates vascular smooth muscle contraction versus relaxation?
Answer: Vasoconstriction is mediated by receptors; vasodilation is mediated by receptors.
Autoreceptor Regulation:
Question: Which adrenergic receptor acts to inhibit the further release of norepinephrine from nerve terminals?
Answer: Presynaptic autoreceptors.
Mechanism of Indirect Sympathomimetics:
Question: How do indirect-acting sympathomimetic drugs elevate adrenergic activity?
Answer: By increasing the concentration of endogenous norepinephrine within the synaptic cleft (via release, reuptake inhibition, or metabolic enzyme blockade) without directly binding postsynaptic receptors.
Epinephrine Auto-injector Adverse Profile:
Question: What constellation of adverse effects is anticipated following an acute injection of an EpiPen?
Answer: Acute anxiety, restlessness, peripheral tremors, severe headache, palpitations, and tachycardia (resembling massive caffeine overconsumption).
Norepinephrine Hemodynamics:
Question: What cardiovascular side effect distinguishes norepinephrine and selective agonists from isoproterenol?
Answer: Reflex bradycardia, triggered by intense peripheral vasoconstriction and high systemic blood pressure activating the arterial baroreceptor reflex.
Receptor Affinity of Norepinephrine:
Question: Norepinephrine exhibits minimal to negligible activity at which adrenergic receptor subtype?
Answer: adrenergic receptors.
Anaphylactic Shock Management:
Question: Which catecholamine is the primary drug of choice for managing acute anaphylactic shock?
Answer: Epinephrine, due to combined (vasoconstriction/edema reversal), (cardiac support), and (bronchodilation) agonist activity.
Parasympathetic Cardiovascular Control:
Question: Which muscarinic receptor subtype mediates negative inotropic and negative chronotropic cardiac effects?
Answer: muscarinic receptors.